The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Forty Seven
Stock and Other Ownership Interests - Forty Seven
Patents, Royalties, Other Intellectual Property - Co-inventor on technologies that have been licensed to Forty Seven Inc
 
Employment - Ab Initio Biotherapeutics; Forty Seven
Leadership - Ab Initio Biotherapeutics
Stock and Other Ownership Interests - Ab Initio Biotherapeutics; Forty Seven
Consulting or Advisory Role - Ligand
Patents, Royalties, Other Intellectual Property - Patent US10316094B2, owned by Stanford University and licensed to Forty Seven, Inc.; Patent US9562087B2, owned by Stanford University and licensed to Ab Initio Biotherapeutics, Inc. (now owned by Ligand Pharmaceuticals); Patent US9845345B2, owned by Ab Initio Biotherapeutics, Inc. (now Ligand Pharmaceuticals).
Travel, Accommodations, Expenses - Forty Seven
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
 
Nehal J. Lakhani
Consulting or Advisory Role - Innovent Biologics
Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Formation Biologics (Inst); Forty Seven (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Northern Biologics (Inst); Pfizer (Inst); Regeneron (Inst); Symphogen (Inst); TaiRx, Inc. (Inst); Tesaro (Inst)
 
Amita Patnaik
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Genentech/Roche (I); Merck; MERCK (I); Novartis; Seagen
Research Funding - Abbvie (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Infinity Pharmaceuticals (Inst); Klus Pharma (Inst); Lilly (Inst); Livzon (Inst); Merck (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Plexxikon (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
John B. Liao
Consulting or Advisory Role - Gilead Sciences (I)
Research Funding - Forty Seven (Inst); Merck Sharp & Dohme (Inst); Regeneron (Inst); Sanofi (Inst)
 
John William Moroney
Consulting or Advisory Role - Clovis Oncology
 
David S. Miller
Consulting or Advisory Role - Alexion Pharmaceuticals; Alexion Pharmaceuticals; AstraZeneca; Clovis Oncology; Eisai; Genentech; Guardant Health; Guardant Health; Incyte; Janssen; Janssen Oncology; Karyopharm Therapeutics; Merck Sharp & Dohme (Inst); Tesaro
Speakers' Bureau - Clovis Oncology; Genentech
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Immunogen (Inst); Janssen (Inst); Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Pfizer (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst)
 
Gini F. Fleming
Honoraria - Curio Science
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); Compugen (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Forty Seven (Inst); Genentech (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Leap Therapeutics (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
(OPTIONAL) Uncompensated Relationships - TTC Oncology
 
Matt Axt
Employment - Forty Seven; Kaiser Permanente (I)
Stock and Other Ownership Interests - Forty Seven
 
Yan V. Wang
Employment - Forty Seven
Stock and Other Ownership Interests - Abbvie; BeiGene
 
Balaji Agoram
Employment - Forty Seven
Stock and Other Ownership Interests - Forty Seven
 
Jens-Peter Volkmer
No Relationships to Disclose
 
Roy Maute
No Relationships to Disclose
 
Andreas Schroeder
Employment - Merck KGaA
Leadership - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
Patents, Royalties, Other Intellectual Property - Merck KGaA
Travel, Accommodations, Expenses - Merck KGaA
 
Isagani Chico
Employment - Forty Seven
Stock and Other Ownership Interests - Forty Seven
 
Mark Chao
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven; Hepatx
Honoraria - D2G Oncology
Consulting or Advisory Role - Chimera Bioengineering
Patents, Royalties, Other Intellectual Property - I am an inventor on several patents from Stanford University that have been licensed to Forty Seven, Inc. I am also an inventor on patents generated from Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven
 
Chris H.M. Takimoto
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven; Johnson & Johnson
Consulting or Advisory Role - Biomotiv
Patents, Royalties, Other Intellectual Property - Patent Proposals filed relating to using anti-CD47 antibodies as cancer therapy at my current company of employment, Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven
 
Kathleen N. Moore
Honoraria - Prime Oncology; Research To Practice
Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca (Inst); Clovis Oncology; Eisai; Genentech/Roche; Immunogen; Janssen Oncology; Merck; OncoMed; Pfizer/EMD Serono; Samumed; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)